Back to overview

3-year Industrial Postdoc Fellowship awarded to Lluís Riera-Ponsatí

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).
Development
Funding

Related topics

Development
Publication
12.1.2026
Neumirna at AES: new data on NMT.001
At the American Epilepsy Society Annual Meeting, Neumirna presented two posters highlighting the potential of its RNA-based approach for drug-resistant epilepsy.
Read full article
Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article
Development
8.7.2025
Neumirna Appoints Ina Brünig-Traebert as Chief Development Officer
With a proven track record in RNA therapies, Ina will guide Neumirna’s transition into clinical-stage development.
Read full article